» Authors » James A Tumlin

James A Tumlin

Explore the profile of James A Tumlin including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 54
Citations 1884
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Furie R, Rovin B, Garg J, Santiago M, Aroca-Martinez G, Zuta Santillan A, et al.
N Engl J Med . 2025 Feb; PMID: 39927615
Background: Obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, provided significantly better renal responses than placebo in a phase 2 trial involving patients with lupus nephritis receiving standard therapy. Methods:...
2.
Charytan D, Winkelmayer W, Granger C, Middleton J, Herzog C, Chertow G, et al.
Kidney Int . 2024 Nov; 107(1):169-179. PMID: 39490411
The optimal approach towards managing serum potassium (sK) and hemodialysate potassium concentrations is uncertain. To study this, adults receiving hemodialysis for three months or more with hyperkalemia (pre-dialysis sK 5.1-6.5...
3.
Ravi K, Tumlin J, Roy-Chaudhury P, Koplan B, Costea A, Kher V, et al.
Kidney360 . 2024 Oct; 5(10):1490-1499. PMID: 39480910
Background: Sudden death accounts for approximately 25% of deaths among maintenance hemodialysis patients, occurring more frequently on hemodialysis days. Higher dialysate bicarbonate (DBIC) may predispose to alkalemia and arrhythmogenesis. Methods:...
4.
Soomro Q, Koplan B, Costea A, Roy-Chaudhury P, Tumlin J, Kher V, et al.
Kidney Med . 2024 Apr; 6(4):100799. PMID: 38572395
Rationale & Objective: The incidence of arrhythmia varies by time of day. How this affects individuals on maintenance dialysis is uncertain. Our objective was to quantify the relationship of arrhythmia...
5.
Rovin B, Barratt J, Heerspink H, Alpers C, Bieler S, Chae D, et al.
Lancet . 2023 Nov; 402(10417):2077-2090. PMID: 37931634
Background: Sparsentan, a novel, non-immunosuppressive, single-molecule, dual endothelin angiotensin receptor antagonist, significantly reduced proteinuria versus irbesartan, an angiotensin II receptor blocker, at 36 weeks (primary endpoint) in patients with immunoglobulin...
6.
Barratt J, Lafayette R, Zhang H, Tesar V, Rovin B, Tumlin J, et al.
Kidney Int . 2023 Jun; 104(2):254-264. PMID: 37263354
Many patients with immunoglobulin A nephropathy (IgAN) progress to kidney failure even with optimal supportive care. An improved understanding of the pathophysiology of IgAN in recent years has led to...
7.
Soomro Q, Bansal N, Winkelmayer W, Koplan B, Costea A, Roy-Chaudhury P, et al.
Kidney360 . 2022 Dec; 3(11):1871-1880. PMID: 36514397
Background: Bradycardia and asystole events are common among patients treated with maintenance hemodialysis. However, triggers of these events in patients on maintenance hemodialysis (HD), particularly during the long interdialytic period...
8.
Koury M, Agarwal R, Chertow G, Eckardt K, Fishbane S, Ganz T, et al.
Am J Hematol . 2022 Jun; 97(9):1178-1188. PMID: 35751858
Patients with chronic kidney disease (CKD) develop anemia largely because of inappropriately low erythropoietin (EPO) production and insufficient iron available to erythroid precursors. In four phase 3, randomized, open-label, clinical...
9.
Koplan B, Winkelmayer W, Costea A, Roy-Chaudhury P, Tumlin J, Kher V, et al.
Kidney Int Rep . 2022 Feb; 7(2):189-199. PMID: 35155858
Introduction: Atrial fibrillation (AF) is common in patients with kidney failure on hemodialysis (KF-HD). We determined both AF incidence and burden in patients with KF-HD using implantable loop recorder (ILR)...
10.
Correa S, Scovner K, Tumlin J, Roy-Chaudhury P, Koplan B, Costea A, et al.
Kidney360 . 2021 Oct; 2(4):695-707. PMID: 34676372
Background: There is a paucity of contemporary data examining electrolyte changes during and immediately after hemodialysis (HD), and their relationship with dialysate prescriptions. The present study examines these relationships. Methods:...